Clinical Trial Update: Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) [Phase 1]

View source ↗

Summary

Phase 1 trial investigating preladenant (MK-3814) alone and with pembrolizumab (MK-3475) in participants with advanced solid tumors; study terminated with poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasm

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• preladenant (preladenant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasm | Phase 1 | Status: TERMINATED | Results posted: 2019-06-05